HC Wainwright Has Bullish Forecast for NERV Q1 Earnings

Minerva Neurosciences, Inc (NASDAQ:NERV) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Minerva Neurosciences in a research report issued on Thursday, March 12th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter, up from their previous forecast of ($0.14). HC Wainwright currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.19) EPS.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.75.

A number of other equities research analysts have also recently commented on NERV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $7.00.

Minerva Neurosciences Trading Up 1.8%

Shares of NASDAQ:NERV opened at $7.83 on Monday. Minerva Neurosciences has a 12-month low of $1.15 and a 12-month high of $12.46. The company has a market capitalization of $338.80 million, a PE ratio of -0.29 and a beta of -0.32. The business has a 50 day moving average of $5.49 and a two-hundred day moving average of $4.09.

Hedge Funds Weigh In On Minerva Neurosciences

Large investors have recently bought and sold shares of the business. Janus Henderson Group PLC purchased a new position in Minerva Neurosciences during the fourth quarter worth approximately $36,000. State Street Corp increased its position in shares of Minerva Neurosciences by 45.4% in the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 7,500 shares in the last quarter. Apella Capital LLC increased its position in shares of Minerva Neurosciences by 87.8% in the third quarter. Apella Capital LLC now owns 39,314 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 18,375 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Minerva Neurosciences during the 4th quarter worth approximately $554,000. Finally, Renaissance Technologies LLC raised its stake in shares of Minerva Neurosciences by 28.1% during the 4th quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 32,700 shares during the period. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.